# Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

Source: https://onco.cc/trials/nct07689539/  
OnCo record `nct07689539` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial in pancreatic cancer, run by Jiangxi Kvvit Pharmaceutical Co., Ltd., not yet recruiting.

## Summary

Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation is a phase 3, randomised interventional study registered as NCT07689539 by Jiangxi Kvvit Pharmaceutical Co., Ltd., with a registry enrolment figure of 360 participants, started 2026-09 and due to reach its primary completion in 2028-07. Interventions recorded: DN022150; Chemotherapy. Conditions listed: Pancreatic Cancer. Primary outcome: Progression-Free Survival (PFS); Overall Survival (OS). Pancreatic eligibility wording from the registry: "Subjects with confirmed KRAS G12D who have received prior systemic therapy for advanced or metastatic pancreatic cancer". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07689539
- Phase: 3
- Setting: A Phase 3, Multicenter, Open-Label, Randomized, Controlled Trial of DN022150 Monotherapy Versus Investigator's Choice Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation
- Sponsor: Jiangxi Kvvit Pharmaceutical Co., Ltd.
- Enrolled: 360

## Sources

- ClinicalTrials.gov NCT07689539: https://clinicaltrials.gov/study/NCT07689539

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07689539.json